- comprehensive market data
- up to date reports
- personal "find a report" service
- reliable and quick
Contact us with your report needs NOW!
+44 1300 321501
Biotechnology, Life Science
Healthcare and Pharmaceutical
Market Research and Corporate Data
Search our store now...
U.S. Market for Peripheral Vascular Devices and AccessoriesBy 2020, the U.S. market for peripheral vascular devices will be worth over $6 billion. The peripheral vascular device market includes stents, percutaneous transluminal angioplasty (PTA) balloon catheters, atherectomy devices, chronic total occlusion devices, stent grafts, surgical grafts, arteriovenous (AV) access thrombectomy devices, inferior vena cava filters, catheters, guidewires, introducer…...read more
U.S. Video, High-Tech and Integrated Operating Room MarketIn 2013, the U.S. market for video, high-tech and integrated OR equipment exceeded $1.8 billion. The video, high-tech and integrated operating room equipment market includes integrated OR components, camera systems, image capture devices, displays, PACS monitors, light sources, medical printers, headlights, lighting, booms, tables, insufflation devices and surgical microscopes. High…...read more
U.S. Market for Dental LasersIn 2013, the total U.S. market for dental laser systems was valued at $72.5 million. This market will beprimarily driven by the soft tissue diode laser market segment. The dental laser device market is divided into three main segments. First is the soft tissue dental laser market, which includes diode…...read more
Antibody Partnering Terms and Agreements Edition: 4…Antibody Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the antibody partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides a detailed understanding and analysis of how and why companies enter antibody partnering deals. The majority of deals are discovery…...read more
Infectious Vaccines Partnering Terms and Agreements Edition: 3…Infectious Vaccines Partnering Terms and agreements report provides a detailed understanding and analysis of how and why companies enter infectious vaccines partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors vaccine technology. These deals tend to…...read more
Distribution Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Edition: 6…Distribution Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the distribution partnering agreements entered into by the worlds leading biopharma companies. The report provides a detailed understand and analysis of how and why companies enter distribution deals. The majority of deals are multicomponent whereby the licensor…...read more
Antibiotics Partnering Terms and Agreements Edition: 2…Antibiotics Partnering Agreements report provides an understanding and access to the antibiotics partnering deals and agreements entered into by the worlds leading healthcare companies. Trends in antibiotics partnering deals Disclosed headlines, upfronts, milestones and royalties by stage of development Antibiotics partnering contract documents Top antibiotics deals by value The Antibiotics…...read more
Physician Views: Revisiting Pfizer's Xeljanz – is the oral revolution gaining traction in rheumatoid arthritis? Just over a year ago – and buoyed by recent FDA approval – expectations for Pfizer's rheumatoid arthritis treatment Xeljanz (tofacitinib) were suitably high. The drug – an oral alternative to injectable biologic therapies with a comparative efficacy and safety profile – was widely expected to help spearhead Pfizer's post-Lipitor…...read more
Consensus Outlook: Prostate Cancer- Competition intensifies in race to the topCharting the Future Prostate Cancer Market LandscapeThe prostate cancer market has experienced substantial changes in the last five years with patent expiries of key compounds and approvals of new novel therapies. The launch of Zytiga (abiraterone acetate), Medivation/Astellas’ Xtandi (enzalutamide) and Algeta/Bayer’s Xofigo are set to trigger the global prostate…...read more
Market Access for Orphan Drugs: assessing the global landscape Their development costs can be high and the market is relative small, yet orphan drugs represent a significant contribution to public health—and the pharmaceutical market.In fact, analysts predict that orphan drugs will account for 15 percent of the global pharmaceutical market by 2018. Yet getting there will not be easy…...read more
KOL Insight: Prostate Cancer: Competition intensifies in race to the top…Prostate Cancer market has seen a number of progressive changes in recent years. The launches of Johnson & Johnson’s Zytiga (abiraterone acetate) and Medivation/Astellas’s Xtandi (enzalutamide) has reinvigorated the post-chemo treatment segment, while launch of the first cancer vaccine Provenge (sipuleucel-T; Dendreon) and Zytiga’s expanded approval had finally given new…...read more
Commercialisation of Biosimilars: strategies for market penetrationTimes, they are a-changin’—at least for the American biological product market.With five major biological products worth a collective US$35 billion in annual sales now facing imminent patent expiration, the market is poised to develop and commericialise biosimilars. With the new abbreviated regulatory pathway now in place in the US, the…...read more
Physician Views: What is reaction among urologists, oncologists to the Xtandi PREVAIL data – can it displace Zytiga in the pre-chemotherapy prostate cancer setting? …prostate cancer market looks poised to enter its next stage of evolution in 2014, with Medivation and Astellas expected to seek approval for their androgen receptor antagonist Xtandi (enzalutamide) for the treatment of castrate-resistant prostate cancer (CRPC) patients in the pre-chemotherapy setting.Johnson & Johnson's Zytiga (abiraterone) – which was approved…...read more
Physician Views: Oncologist reaction to Roche's Gazyva – US approval and new late-stage data versus RituxanRoche’s efforts to enhance its dominance of the haematological cancer market received notable momentum last week when the company gained FDA approval for Gazyva as a first-line treatment for chronic lymphocytic leukemia (CLL) - see ViewPoints: Roche ticks another box in biosimilar defence/cancer domination strategy as FDA approves 'son of…...read more
Physician Views: As Tecfidera approaches a critical juncture in Europe, how are neurologist perceptions towards Biogen Idec's MS drug shaping up? Sales of Biogen Idec’s multiple sclerosis therapy Tecfidera may continue to exceed initial expectations in the US market, but in Europe a shadow of doubt has been cast across the future of the drug.On the company’s Q3 earnings call, management confirmed that the European Medicines Agency's Committee for Medicinal Products…...read more
Physician Views: What opportunity for Novo Nordisk's Victoza in obesity? Analysts have notably mixed opinions on the commercial opportunity, but one of the more intriguing near-term catalysts for Novo Nordisk is potential FDA approval of Victoza (its GLP-1 anti-diabetic) for the treatment of obesity.Most recent Phase III data – published in May – supports a consensus view that Victoza will…...read more
Physician Views: How have cardiologists, internal medicine specialists and general practitioners reacted to the new AHA/ACC cholesterol management guidelines Since being announced last week, new cardiovascular disease treatment guidelines from the American Heart Association (AHA) and the American College of Cardiology (ACC) have been the subject of much debate.Rather than focus on treating patients towards a target LDL level (as is the case with current recommendations), the guidelines recommend…...read more
Physician Views: Entering the post-interferon era – will Gilead Sciences dominate hepatitis C? Consensus forecasts indicate that Gilead Sciences will dominate the market for all oral, interferon-sparing hepatitis C therapies, with this success expected to be centred on its combination sofosbuvir plus ledipasvir franchise. Final Phase III data for this combination therapy are expected to emerge in early 2014, with potential approval secured…...read more
Pharma and the Changing US Payer Environment: Meeting the demands of Accountable Care Organizations (ACOs)There’s a revolution happening...and it’s going to change the way pharma thinks.As the accountable care movement gains traction in the United States and physicians eye a possible $1 trillion in saved healthcare costs, ACOs are emerging quickly. There is no question that knitting together improved quality of care, real world…...read more
Global Bioinformatics Market 2014-2018TechNavio's analysts forecast the Global Bioinformatics market to grow at a CAGR of 26.15 percent over the period 2013-2018. One of the key factors contributing to this market growth is the decreasing cost of genetic sequencing. The Global Bioinformatics market has also been witnessing the increasing outsourcing of bioinformatics services…...read more
Global Breast Implants Market 2014-2018TechNavio forecasts The Global Breast Implants Market with a CAGR of 6.08 percent for the period 2013–2018. Several driving factors and trends will contribute to this growth—all of which will be outlined with detail in this report. TechNavio’s analysts use a unique methodology to scrutinize individual vendor performance, trends, drivers…...read more
Global Imaging Biomarkers Market 2014-2018TechNavio's analysts forecast the Global Imaging Biomarkers market to grow at a CAGR of 15.09 percent over the period 2013-2018. One of the key factors contributing to this market growth is the increasing prevalence of cancer. The Global Imaging Biomarkers market has also been witnessing the emergence of personalized medicines…...read more
Global Nutraceuticals Market 2014-2018TechNavio's analysts forecast the Global Nutraceutical market to grow at a CAGR of 6.30 percent over the period 2013-2018. One of the key factors contributing to this market growth is the increasing global ageing population. The Global Nutraceutical market has also been witnessing the increase in the nutraceutical product development…...read more
Dental Implants Market in North America 2014-2018TechNavio forecasts The Dental Implants Market in North America 2014-2018 with a CAGR of 9.55 percent for the period 2013-2018. Several driving factors and trends will contribute to this growth—all of which will be outlined with detail in this report. TechNavio’s analysts use a unique methodology to scrutinize individual vendor…...read more
Global E-cigarette Market 2014-2018 TechNavio forecasts The Global E-cigarette Market 2014-2018 with a CAGR of 30.56 percent for the period 2013-2018. Several driving factors and trends will contribute to this growth—all of which will be outlined with detail in this report. TechNavio’s analysts use a unique methodology to scrutinize individual vendor performance, trends, drivers…...read more
Easy Payment Options
Or we can raise a pro forma invoice if you prefer.
Buy With Confidence
BioPortfolio has been selling market reports for over 16 years from the world's leading market research companies.
Our team will work with you to source the best report for your needs. We can liaise with publishers to obtain sample pages and negotiate discounts where available.
With over 15,000 visitors to our websites every day, BioPortfolio is the world's leading biotech, healthcare and medical resource online.